Launch Sequence Aphrodisia Capsules — Class I drug recall D-1338-2022
Terminated recall by Loud Muscle Science, reported 2022-07-27, distributed nationwide. Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in F
| Recall number | D-1338-2022 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Loud Muscle Science, Hauppauge, NY, United States |
| Recall initiated | 2022-06-27 |
| Classified | 2022-08-15 |
| Reported by FDA | 2022-07-27 |
| Terminated | 2023-02-08 |
| Distributed | Nationwide (US) |
| Countries outside the US | CA |
| Reason classes | undeclared allergen, unapproved product |
| UPC / GTIN / UDI-DI | 00661020846957 |
| Lot numbers | 2022104 |
| Expiration dates | 2025-04 |
Product
Launch Sequence Aphrodisia Capsules, 4-count tins, ASIN B07QB3S2LV, UPC Code 661020846957.
Reason for recall
Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1338-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.